Cargando…

Molecular dynamics simulations and docking of non-nucleoside reverse transcriptase inhibitors (NNRTIs): a possible approach to personalized HIV treatment

Detalles Bibliográficos
Autores principales:	Roessler, Florian D, Korb, Oliver, Bender, Andreas, Maentele, Werner, Bond, Peter J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341254/ http://dx.doi.org/10.1186/1758-2946-4-S1-P32

Ejemplares similares

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
por: Zhuang, Chunlin, et al.
Publicado: (2020)

Computational studies on non-nucleoside analogs of pyrimidine as NNRTIs against HIV-1
por: Srivastava, Ritika, et al.
Publicado: (2014)

Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study
por: Riou, Julien, et al.
Publicado: (2021)

Correction to: Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study
por: Riou, Julien, et al.
Publicado: (2021)

Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design
por: Singh, Udaya Pratap, et al.
Publicado: (2011)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors
por: BHARDWAJ, Nivedita, et al.
Publicado: (2020)

A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH Activity
por: Wright, David W., et al.
Publicado: (2013)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
por: Molès, Jean-Pierre, et al.
Publicado: (2009)

An Alternative HIV-1 Non-Nucleoside Reverse Transcriptase Inhibition Mechanism: Targeting the p51 Subunit
por: Chan, Kwok-Fong, et al.
Publicado: (2020)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

Computational modelling, green synthesis and biological activity of arylsulfonilamides as NNRTIs against HIV-1
por: Singh, Anuradha, et al.
Publicado: (2014)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Docking study of HIV-1 reverse transcriptase with phytochemicals
por: Seal, Abhik, et al.
Publicado: (2011)

Ensemble docking revisited
por: Korb, Oliver, et al.
Publicado: (2010)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
por: Jordaan, Maryam A., et al.
Publicado: (2020)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
por: Wright, David W., et al.
Publicado: (2012)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
por: Zhao, Chenglong, et al.
Publicado: (2020)

Reverse transcriptases of retroviruses and retroelements: an evolutionary perspective
por: Arkhipova, Irina R
Publicado: (2009)

Multi-body interactions in molecular docking: treatment of water molecules and multiple ligands
por: Korb, Oliver, et al.
Publicado: (2008)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
por: Dwivedi, Richa, et al.
Publicado: (2022)

Abstracts from the current global literature: Mitochondrial toxicities due to nucleoside reverse transcriptase inhibitors
por: Jain, Sonia, et al.
Publicado: (2012)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
por: Garforth, Scott J., et al.
Publicado: (2014)

Nucleoside reverse transcriptase inhibitor-induced rat oocyte dysfunction and low fertility mediated by autophagy
por: Tang, Li, et al.
Publicado: (2017)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
por: Petrou, Anthi, et al.
Publicado: (2019)

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV
por: De Francesco, Davide, et al.
Publicado: (2021)

The assessment of computationally derived protein ensembles in protein-ligand docking
por: Sander, Barbara, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_raqp5vggegpt9o49mio3su6g2l